Information about Targol 
Each 5 mg tablet contains 5.49 mg prasugrel hydrochloride, equivalent to 5 mg prasugrel base.
Each 10 mg tablet contains 10.98 mg prasugrel hydrochloride, equivalent to 10 mg prasugrel base.

Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.

Prasugrel is indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows:
Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI).
Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed precutaneous coronary intervention (PCI).
Prasugrel Unipharma has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (Ml), or nonfatal stroke compared to clopidogrel.

Prasugrel Unipharma is contraindicated in patients with:
Active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
A history of prior transient ischemic attack or stroke. Patients who experience a stroke or transient ischemic attack while on Prasugrel Unipharma generally should have therapy discontinued.

Dosage and Administration:
Initiate Prasugrel Unipharma treatment as a single 60 mg oral loading dose and then continue at 10 mg orally once daily. Patients taking Prasugrel should also take aspirin (75 mg to 325 mg) daily. Prasugrel Unipharma may be administered with or without food.
Dosing in Low Weight Patients
Lowering the maintenance dose from 10 mg to 5 mg in patients weighing less than 60 kg, should be considered.


For two strength Package of 14 film coated tablets